Bone Density, Bone Markers and Bone Radiological Features in Mastocytosis
Author(s) -
Christer Johansson,
Gösta Roupe,
Göran Lindstedt,
Dan Mellström
Publication year - 1996
Publication title -
age and ageing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.014
H-Index - 143
eISSN - 1468-2834
pISSN - 0002-0729
DOI - 10.1093/ageing/25.1.1
Subject(s) - systemic mastocytosis , medicine , osteoporosis , bone resorption , bone mineral , prostaglandin d2 , endocrinology , osteosclerosis , bone remodeling , bone density , pathology , bone marrow , prostaglandin
We examined the association between severity of disease in mastocytosis and skeletal manifestation and bone markers in 16 patients varying in extent of mastocytosis as determined by the urine excretion of methylimidazoleacetic acid. Both osteoporosis and osteosclerosis were found. Bone density in the hip was significantly higher (p < 0.05) in both men and women with an enhanced histamine metabolite excretion. Patients with only moderately increased mast cell mass had low bone mineral density in the hip, osteoporosis and vertebral fractures. The different skeletal disease patterns in mastocytosis might be the effect on osteoblasts and osteoclasts of biologically active substances. Mast cells release a number of vasoactive substances, including histamine which promotes osteoblasts and heparin and prostaglandin D2 which induce bone resorption by activation of osteoclasts. Systemic mastocytosis is a rare disease characterized by multi-organ infiltration by mast cells and with varying skeletal manifestations including osteoporosis. Treatment with bisphosphonates may be beneficial in arresting osteoporosis in this disorder.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom